Sabuwar Jiyya da Nazarin Rheumatoid Arthritis: Binciken Bincike

Wadatacce

• Masu hana JAK suna ba da taimako
• BTK mai hanawa a ci gaba
• Neurostimulation yana nuna alƙawari
• Omega-3 fatty acid na iya taimakawa
• RA magunguna suna da alaƙa da fa'idodin lafiyar zuciya
• Takeaway

Rheumatoid amosanin gabbai (RA) wani yanayi ne mai ɗorewa wanda ke haifar da kumburi, kumburi, da zafi. Babu sanannen magani na RA - amma akwai hanyoyin magancewa don taimakawa sauƙaƙe alamomin, iyakance lalacewar haɗin gwiwa, da inganta ƙoshin lafiya gabaɗaya.

Yayinda masana kimiyya ke ci gaba da haɓakawa da haɓaka magunguna na RA, likitanku na iya ba da shawarar canje-canje ga shirin maganinku.

Karanta don koyo game da wasu sabbin bincike da sababbin zaɓuɓɓukan magani don wannan yanayin.

Masu hana JAK suna ba da taimako

Mutane da yawa tare da RA suna amfani da nau'in cututtukan cututtukan ƙwayoyin cuta (DMARD) da ake kira methotrexate. Amma a wasu lokuta, magani tare da methotrexate shi kadai bai isa ya sarrafa alamun ba.

Idan kana shan maganin methotrexate kuma har yanzu kana fuskantar matsakaiciyar cuta mai tsanani na RA, likitanka na iya ba da shawarar ƙara mai hana janus kinase (JAK) a cikin shirin maganin ka. Masu hana JAK sun taimaka dakatar da halayen sunadarai wadanda ke haifar da kumburi a jikinku. Methotrexate yayi wannan, shima, amma ta wata hanya daban. Ga wasu mutane, masu hana JAK aiki sosai.

Zuwa yau, Hukumar Abinci da Magunguna (FDA) ta amince da nau'ikan masu hana JAK guda uku don magance RA:

• tofacitinib (Xeljanz), an amince da shi a shekarar 2012
• baricitinib (Olumiant), an amince da shi a cikin 2018
• upadacitinib (Rinvoq), an amince da shi a cikin 2019

Masu bincike suna ci gaba da nazarin waɗannan magungunan don sanin yadda suke kamanta juna, da kuma sauran zaɓuɓɓukan magani. Misali, masana kimiyya sun gano kwanan nan cewa hadewar methotrexate da upadacitinib sun fi tasiri fiye da methotrexate da adalimumab don rage ciwo da inganta aiki a cikin mutane masu RA. Fiye da mutane 1,600 tare da RA suka halarci wannan binciken.

Hakanan ana ci gaba da gwaji na asibiti don haɓaka sabbin masu hana JAK, ciki har da magani na gwaji wanda aka fi sani da filgotinib. A cikin gwajin gwaji na III na kwanan nan, an gano filgotinib ya fi tasiri fiye da placebo don magance RA a cikin mutanen da suka taɓa yin ƙoƙari ɗaya ko fiye da DMARDs. Ana buƙatar ƙarin bincike don nazarin aminci da ingancin wannan magani na gwaji.

Don ƙarin koyo game da fa'idodi da haɗarin haɗarin ɗaukar mai hana JAK, yi magana da likitanka. Za su iya taimaka maka ka koya idan irin wannan magani na iya zama kyakkyawan zaɓi a gare ku.

BTK mai hanawa a ci gaba

Bruton's tyrosine kinase (BTK) enzyme ne wanda ke taka rawa wajen ci gaban kumburi. Don toshe aikin BTK, masu bincike suna haɓakawa da gwada mai hana BTK wanda aka sani da fenebrutinib.

Karatun farko ya nuna cewa fenebrutinib na iya samar da wani zabin magani na RA. Wani rukuni na masu bincike na duniya kwanan nan sun kammala gwajin gwaji na zamani na II don yin nazari kan aminci da ingancin fenebrutinib don magance wannan yanayin. Sun gano cewa fenebrutinib yana da karɓaɓɓe amintacce kuma mai tasirin tasiri.

Binciken ya gano cewa idan aka hada shi da methotrexate, fenebrutinib ya fi tasiri fiye da wuri don magance alamun RA. Fenebrutinib yana da ƙimar aiki daidai kamar adalimumab.

Ana buƙatar ƙarin bincike don nazarin aminci da inganci na fenebrutinib.

Neurostimulation yana nuna alƙawari

Wasu mutane suna gwada magunguna da yawa don magance RA, ba tare da nasara ba.

A matsayin madadin magunguna, masu bincike suna nazarin fa'idodi da haɗarin haɗarin jijiyoyin farji don magance RA. A wannan tsarin kulawar, ana amfani da motsin lantarki don motsa jijiyar farji. Wannan jijiya yana taimakawa wajen daidaita kumburi a jikinka.

Masana kimiyya kwanan nan sun gudanar da bincike na farko a cikin mutum game da motsa jijiyoyin jiki don magance RA. Sun dasa ƙaramin neurostimulator ko abin ƙyama a cikin mutane 14 tare da RA. Shida daga cikin waɗannan mutanen an yi musu magani tare da motsa jijiyar farji sau ɗaya a rana tsawon makonni 12.

Daga cikin mahalarta waɗanda ke karɓar motsawar jijiyoyin yau da kullun, hudu daga cikin mahalarta shida sun sami ci gaba a cikin alamun RA. Wasu 'yan mahalarta sun sami mummunan lamura yayin jiyya, amma babu ɗayan abubuwan da aka ruwaito da suka kasance mai tsanani ko na dindindin.

Omega-3 fatty acid na iya taimakawa

Bugu da ƙari da shan magungunan da aka ba ku, nazarin ya nuna cewa ƙara ƙarin omega-3 zuwa aikinku na yau da kullun na iya taimakawa iyakance alamun bayyanar RA.

Amfani da Omega-3 mai amfani da mai ya danganta da rage kumburi a jiki. Lokacin da masu bincike daga Jami'ar Houston suka sake nazarin bincike kan karin omega-3, sun sami gwaji na asibiti 20 wadanda suka maida hankali kan RA musamman. A cikin 16 daga gwaji 20, haɗin omega-3 yana da alaƙa da manyan ci gaba a cikin alamun RA.

Binciken bincike na kwanan nan ya samo hanyar haɗi tsakanin ƙarin omega-3 da rage ayyukan cuta a cikin mutane tare da RA. A taron shekara-shekara na ACR / ARP na 2019, masu bincike sun ba da rahoton sakamakon binciken rajista na dogon lokaci na mutane 1,557 tare da RA. Mahalarta wadanda suka ba da rahoton shan abubuwan karin omega-3 suna da ƙananan ƙwayoyin cuta, ƙananan haɗin kumburi, da ƙananan raɗaɗin raɗaɗi a matsakaici fiye da waɗanda ba su ɗauki ƙarin omega-3 ba.

RA magunguna suna da alaƙa da fa'idodin lafiyar zuciya

Wasu magungunan RA na iya samun fa'ida ga zuciyar ku, har ma da haɗin ku. Dangane da sabbin karatu guda biyu da aka gabatar a taron shekara-shekara na 2019 ACR / ARP, waɗannan magunguna sun haɗa da methotrexate da hydroxychloroquine.

A cikin binciken daya, masu bincike sun bi tsoffin sojoji 2,168 tare da RA daga 2005 zuwa 2015. Sun gano cewa mahalarta da suka karɓi jiyya tare da methotrexate ba za su iya fuskantar abubuwan da suka shafi zuciya ba, kamar ciwon zuciya ko bugun jini. Haka kuma mahalarta da suka karɓi maganin ba su da sauƙi a kai su asibiti saboda ciwon zuciya.

A wani binciken, masu binciken Kanada sun binciko bayanan rajista da aka tattara daga ƙungiyoyi uku: mutane da RA, mutanen da ke da tsarin lupus erythematosus (SLE), da kuma kulawar lafiya ba tare da wani yanayin ba. Mutanen da ke da RA ko SLE waɗanda aka yi wa magani tare da hydroxychloroquine suna da raguwar haɗarin abubuwan da suka shafi zuciya, kamar ciwon zuciya ko bugun jini.

Takeaway

Nasarori a cikin kimiyyar likitanci na iya taimaka wa masu bincike don inganta hanyoyin da ke akwai da haɓaka sababbin hanyoyin magance RA.

Don ƙarin koyo game da sababbin zaɓuɓɓukan magani don RA, yi magana da likitanka. Zasu iya taimaka muku fahimtar fa'idodi da haɗarin dake tattare da daidaita tsarin shirinku. Hakanan suna iya ba da shawarar canje-canje na rayuwa, irin su shan sigari ko turɓaya, don taimaka muku jin daɗin mafi kyawun lafiyar da ingancin rayuwa tare da wannan yanayin.